Skip to main content
. 2023 Apr 17;3(3):100310. doi: 10.1016/j.xops.2023.100310

Table 1.

Baseline Characteristics of Control Subjects and Patients with POAG

Control (n = 38) POAG (n = 32) P value
Systemic characteristics
 Age (yrs) 70.3 ± 8.4 68.8 ± 11.1 0.64
 Gender (% male) 39.5 62.5 0.055
 Race (% White) 97.4 78.1 0.01
 Body mass index (kg/m2) 25.8 ± 4.3 25.7 ± 3.8 0.89
 Systemic hypertension (%) 51.4 37.5 0.29
Ophthalmic characteristics
 Visual acuity (Snellen, logMAR) 20/23,
0.06 ± 0.08
20/22,
0.04 ± 0.07
0.18
 Spherical equivalent (diopters) -0.01 ± 1.8 0.1 ± 2.3 0.85
 Prior cataract surgery in ≥ 1 eye (%) 60.0 46.9 0.48
 Prior penetrating glaucoma surgery in ≥ 1 eye (%) - 18.7 -
 Prior minimally invasive glaucoma surgery in ≥ 1 eye (%) - 28.1 -
 Intraocular pressure-lowering medications - 2.0 ± 1.3 -
 Intraocular pressure (mmHg) 15.3 ± 2.2 13.3 ± 2.8 0.003
 Cup-to-disc ratio 0.3 ± 0.1 0.7 ± 0.1 < 0.001
 Retinal nerve fiber layer thickness (μm) 99.8 ± 10.0 76.2 ± 13.3 < 0.001
 HVF MD (dB) - -4.7 ± 4.0 -
OCTA measurements
 cpVD (%) 43.0 ± 2.7 40.0 ± 2.9 < 0.001

All data are presented as mean ± standard deviation unless specified otherwise. Significant P values are in bold.

cpVD = circumpapillary vessel density; HVF = Humphrey visual field; logMAR = logarithm of the minimum angle of resolution; MD = mean deviation; OCTA = OCT angiography; POAG = primary open-angle glaucoma.

Only calculated for patients who had both eyes phakic as an average of spherical equivalent of both eyes.

Intraocular pressure was measured on the day of blood draw. All patients with POAG received treatment for intraocular pressure.

Available for 78.9% controls (n = 30) and 87.5% patients with POAG (n = 28).